PD 163070, a potent endothelin-A selective antagonist with long duration of action.

被引：0
|
作者：
Lee, C [1 ]
Cheng, XM [1 ]
Repine, J [1 ]
Bradford, L [1 ]
Reyner, E [1 ]
Stewart, B [1 ]
Hallak, H [1 ]
Welch, KM [1 ]
Walker, D [1 ]
Haleen, S [1 ]
Doherty, A [1 ]
机构：
[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1997年 / 213卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：195 / MEDI
页数：1
相关论文
共 50 条
  • [1] PD-156707: A selective endothelin-A receptor antagonist
    Uprichard, ACG
    Metz, AL
    Hallak, H
    Haleen, SJ
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (02): : 89 - 104
  • [2] Atrasentan - A novel selective endothelin-A receptor antagonist
    Abdelghany, O
    FORMULARY, 2005, 40 (11) : 376 - +
  • [3] Amelioration of hepatorenal syndrome with selective endothelin-A antagonist
    Soper, CPR
    Latif, AB
    Bending, MR
    LANCET, 1996, 347 (9018): : 1842 - 1843
  • [4] Isoindolines: A new series of potent and selective endothelin-A receptor antagonists
    Kukkola, PJ
    Bilci, NA
    Ikler, T
    Savage, P
    Shetty, SS
    DelGrande, D
    Jeng, AY
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (13) : 1737 - 1740
  • [5] Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
    Barst, Robyn J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 95 - 109
  • [6] Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist
    Sudoh, K
    Yuyama, H
    Noguchi, Y
    Fujimori, A
    Ukai, H
    Ohtake, A
    Sato, S
    Sasamata, M
    Miyata, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 : S390 - S393
  • [7] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [8] Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists
    Tasker, AS
    Sorensen, BK
    Jae, HS
    Winn, M
    vonGeldern, TW
    Dixon, DB
    Chiou, WJ
    Dayton, BD
    Calzadila, S
    Hernandez, L
    Marsh, KC
    WuWong, JR
    Opgenorth, TJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (03) : 322 - 330
  • [9] Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, bosentan, in experimental renal ischemia reperfusion injury
    Kazimoglu, H.
    Uysal, E.
    Dokur, M.
    Gurer, A. O.
    Batcioglu, K.
    Uyumlu, B. A.
    Petekkaya, E.
    Karadag, M.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2020, 121 (08): : 547 - 553
  • [10] Attenuation of endothelin expression and histologic changes by administration of a selective endothelin-A receptor antagonist in pig pancreas transplantation
    Uhlmann, D
    Ludwig, S
    Escher, E
    Armann, B
    Gäbel, G
    Teupser, D
    Tannapfel, A
    Pietsch, UC
    Hauss, J
    Witzigmann, H
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (06) : 2362 - 2363
12345